Ursula McCormick
Psychiatric/Mental Health · Bloomington, INNPI 1689658874
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 291 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,997 and has fallen 66.0% since, to $680 in 2025. Among psychiatric/mental health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 291 payments — averaging $26.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$879
- Otsuka America Pharmaceutical, Inc.$845
- AbbVie$643
- Neurocrine Biosciences, Inc.$579
- plus $2K from 16 others
What the payments were for
- Food & beverage$7,33696%
- Education$3354%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 37 | $1,330 |
| Teva Pharmaceuticals USA, Inc. | 37 | $1,172 |
| Alkermes, Inc. | 28 | $879 |
| Otsuka America Pharmaceutical, Inc. | 37 | $845 |
| AbbVie | 35 | $643 |
| Neurocrine Biosciences, Inc. | 24 | $579 |
| Johnson & Johnson | 19 | $464 |
| Axsome Therapeutics, Inc. | 12 | $461 |
| Lundbeck LLC | 13 | $238 |
| E.r. Squibb & Sons, L.L.C. | 5 | $222 |
| Sunovion Pharmaceuticals Inc. | 13 | $162 |
| Indivior Inc. | 6 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $110 |
| Ironshore Pharmaceuticals Inc. | 2 | $99 |
| Supernus Pharmaceuticals, Inc. | 6 | $99 |
| Novo Nordisk | 1 | $81 |
| Vanda Pharmaceuticals Inc. | 3 | $72 |
| Noven Therapeutics, LLC | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| UCB, Inc. | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$763
- LYBALVI$509
- ARISTADA$429
- Austedo XR$240
- REXULTI$125
- VRAYLAR$122
- AUSTEDO$114
- ARISTADA INITIO$107
How this compares
$7,671 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 176 | $551,720 |
| Invega TrinzaPaliperidone Palmitate | 24 | $175,491 |
| Austedo XrDeutetrabenazine | 11 | $123,647 |
| RexultiBrexpiprazole | 76 | $116,824 |
| AustedoDeutetrabenazine | 14 | $98,545 |
| VraylarCariprazine Hcl | 34 | $50,835 |
| Abilify MaintenaAripiprazole | 14 | $40,668 |
| TrintellixVortioxetine Hydrobromide | 49 | $25,436 |
| JanuviaSitagliptin Phosphate | 12 | $7,126 |
| XareltoRivaroxaban | 12 | $7,056 |
| Lurasidone Hcl | 42 | $6,216 |
| Atomoxetine Hcl | 17 | $5,815 |
| Paliperidone ErPaliperidone | 46 | $5,052 |
| Aripiprazole | 57 | $4,850 |
| Clozapine | 59 | $4,727 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Xarelto | $464 | $734,267212 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,172 | $222,19325 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $845 | $157,49190 claims |
| AbbVieVraylar | $643 | $50,83534 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $110 | $25,43649 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Bloomington
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Trina GreenwaldMarion$107K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.